What is Igenbio?
Igenbio, Inc. operates at the forefront of genomic services, offering comprehensive solutions in whole genome sequencing, RNA sequencing, and microbiome analysis. Their expertise extends to providing advanced bioinformatics solutions and support for regulatory filings, serving a diverse clientele that includes academic, governmental, and industrial institutions. The company's proprietary informatics platform, ERGO, is instrumental in driving cutting-edge research and enhancing the delivery of their genomic services. Igenbio's established reputation is evidenced by its trusted partnerships with leading global institutions and Fortune 500 companies across critical sectors such as food and agriculture, bioremediation, and biodefense.
How much funding has Igenbio raised?
Igenbio has raised a total of $57K across 1 funding round:
Debt
$57K
Debt (2021): $57K with participation from PPP
What's next for Igenbio?
With the recent influx of substantial expansion capital, Igenbio is poised for significant operational scaling and market expansion. The company's strategic focus will likely involve enhancing its bioinformatics platform, broadening its service portfolio, and potentially exploring new industry verticals where genomic analysis can provide critical insights. This investment at the Series B/C stage suggests a commitment to solidifying its market leadership and advancing its technological capabilities to meet the growing demand for sophisticated genomic solutions. Future developments may also include strategic partnerships or acquisitions to further accelerate growth and innovation in the rapidly evolving field of genomics.
See full Igenbio company page
